Fundraising Fox

Singletto

Seattle, US · Founded 2020 · Washington corporation · 1 known investors

Singletto develops Oxafence Active Protection™, a materials-applied antimicrobial technology integrated into protective materials such as masks, using photodynamic approaches to enable active microbial inactivation during use. The company licenses its platform technology to healthcare, operational, and emerging markets where traditional antimicrobial solutions have proven limited.

BiotechDeep TechHealthtechMedical DevicesNew Materials

Founders & leadership

JBJohn Bjornson
John BjornsoninChief Executive Officer
JC
James ChenCo-founder, MD
TL
Tom LendvayChief Medical Officer

Investors · 1

SeaChange$250K – $1M

Reported raises · per SEC filings

Form D private placements

$11M disclosed across 6 rounds · 2020–2026

▶$100KraisedMar 2026 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael ButlerDirector
  • Thomas Sean LendvayExecutive Officer, Director
  • John David BjornsonExecutive Officer, Director
  • James David ChenExecutive Officer, Director
Offering amount
$10M
Amount sold
$100K
First sale
Mar 2026
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.5MraisedApr 2025 · 80 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas Sean LendvayExecutive Officer, Director
  • James David ChenExecutive Officer, Director
  • John David BjornsonExecutive Officer, Director
Offering amount
$13.4M
Amount sold
$10.5M
First sale
Apr 2025
Incorporated
Corporation, Washington, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$65KraisedJan 2024 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • James David ChenExecutive Officer, Director
  • Thomas Sean LendvayExecutive Officer, Director
  • John David BjornsonExecutive Officer, Director
Offering amount
$10M
Amount sold
$65K
First sale
Jan 2024
Incorporated
Corporation, Washington, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$200KraisedMay 2023 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John David BjornsonExecutive Officer, Director
  • James David ChenExecutive Officer, Director
  • Thomas Sean LendvayExecutive Officer, Director
Offering amount
$5M
Amount sold
$200K
First sale
May 2023
Incorporated
Corporation, Washington, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50KraisedAug 2021 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John David BjornsonExecutive Officer, Director
  • James David ChenExecutive Officer, Director
  • Thomas Sean LendvayExecutive Officer, Director
Offering amount
$5M
Amount sold
$50K
First sale
Aug 2021
Incorporated
Corporation, Washington, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$75KraisedOct 2020 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas Sean LendvayExecutive Officer, Director
  • James David ChenExecutive Officer, Director
  • John David BjornsonExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$75K
First sale
Sep 2020
Incorporated
Corporation, Washington, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
University of British Columbia9 shared keywordsThe University of British Columbia is a public university offering academic programs, research, and campus events across areas such as environmental science, business, music, and agriculture. It serves students, faculty, staff, and the public in British Columbia, Canada.

Companies competing with Singletto for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Singletto has filed a notice of an exempt offering of securities to raise $10 Million in New Funding. - intelligence360intelligence360.news · Mar 2026Seattle Startup Singletto Launches FDA-Approved Virus-Killing Face Masks on Amazonwebpronews.com · Oct 2025With $10M and DARPA backing, Singletto offers antiviral masks on Amazongeekwire.com · Oct 2025

Frequently asked questions

What does Singletto do?
Singletto develops Oxafence Active Protection™, a materials-applied antimicrobial technology integrated into protective materials such as masks, using photodynamic approaches to enable active microbial inactivation during use. The company licenses its platform technology to healthcare, operational, and emerging markets where traditional antimicrobial solutions have proven limited.
Who are Singletto's investors?
Singletto's investors include SeaChange.
How much funding has Singletto raised?
Singletto has disclosed $11M raised across 6 rounds.
Where is Singletto headquartered?
Singletto is headquartered in Seattle, US.